GlassScriptPhysician profile
Donald L Cohen
NPI 1093703373
$2,268.05
in general payments reported to CMS, 2019-2025
27 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $198 · 2021: $387 · 2022: $627 · 2023: $225 · 2024: $337 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $948.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $356.20 | 2020-2025 | Mounjaro, Zepbound |
| Organogenesis INC. | $304.34 | 2021-2022 | |
| Abbvie INC. | $237.52 | 2021-2024 | Creon, Linzess |
| Novo Nordisk INC | $185.68 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $177.22 | 2024-2025 | Voquezna |
| Amgen INC. | $174.88 | 2019-2025 | Evenity, Prolia, Prolia |
| Astrazeneca Pharmaceuticals LP | $149.48 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $98.88 | 2019-2022 | |
| Allergan, INC. | $60.80 | 2019-2020 | |
| Abbott Laboratories | $54.28 | 2023 | Freestyle Libre 2 |
| Inspire Medical Systems, INC. | $50.59 | 2025 | Inspire |
| Nestle Healthcare Nutrition INC. | $42.43 | 2021-2022 | |
| Exact Sciences Corporation | $40.18 | 2023-2024 | Cologuard Collection Kit |
| Eisai INC. | $33.57 | 2021-2022 | |
| Pfizer INC. | $32.47 | 2020-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $31.40 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.19 | 2021-2024 | Xifaxan |
| Nevro Corp. | $28.88 | 2022 | |
| Amarin Pharma, INC. | $26.89 | 2020 | |
| Axsome Therapeutics, INC. | $25.37 | 2023 | Auvelity |
| Boston Scientific Corporation | $24.38 | 2025 | Watchman Access System |
| Idorsia Pharmaceuticals US INC | $21.07 | 2022 | |
| Glaxosmithkline, LLC. | $19.62 | 2023 | Shingrix, Arexvy |
| Astellas Pharma US INC | $18.77 | 2022 | |
| Vivus LLC | $16.17 | 2020 | |
| Tolmar, INC. | $15.95 | 2025 | Jatenzo |
| Amneal Pharmaceuticals LLC | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.